Company Overview of Tensha Therapeutics, Inc.
Tensha Therapeutics, Inc. develops anti-cancer compound for curing acute myeloid leukemia. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
55 Cambridge Parkway
Cambridge, MA 02142
Founded in 2011
Key Executives for Tensha Therapeutics, Inc.
Compensation as of Fiscal Year 2014.
Tensha Therapeutics, Inc. Key Developments
Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
Nov 20 13
Tensha Therapeutics announced that it has begun the first clinical trial of its small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor, TEN-010 for the treatment of cancer. The trial is designed to assess the safety, tolerability and anti-tumor activity of TEN-010 in patients with advanced solid tumors that are refractory or intolerant to standard/approved therapies and NUT midline carcinoma (NMC), a highly aggressive cancer with very limited treatment options. Bromodomains, which are modules contained within epigenetic proteins, play critical roles in influencing gene transcription by functioning as 'readers' of epigenetic marks. Once bound to chromatin, these bromodomain-containing proteins can influence gene expression. Tensha's Founder, James Bradner, MD, an Assistant Professor at Harvard Medical School and Investigator at the Dana-Farber Cancer Institute, was the first to recognize the broad potential of small molecule BET bromodomain inhibitors across a range of therapeutic areas. Dr. Bradner's seminal work identified NMC as sensitive to BET bromodomain inhibition. NMC is a rare, invariably fatal cancer caused in the majority of cases by a gene translocation event that results in the expression of the NUT protein fused to the BET bromodomains of BRD3 or BRD4. Subsequent studies from Dr. Bradner's and collaborating laboratories have established BET bromodomain inhibition as a therapeutic strategy to target Myc overexpression and demonstrated the potential of this approach to other cancers, including multiple myeloma, acute myeloid leukemia, non-small cell lung cancer and neuroblastoma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries